Abstract:Background and Objectives Our aim in this study was to investigate the usefulness of circulating tumor (ct) DNA methylation analysis for predicting long‐term outcomes after resection in Stage IV colorectal cancer (CRC). Methods Methylation analyses were performed on 95 plasma samples from patients with CRC who underwent surgery. The methylation status (relative methylation value: RMV) of CpG within the promoter region of three genes (CHFR, SOX11, and CDO1) was assessed to quantitative methylation‐specific PCR (qMSP) analysis. Results In the patients who had undergone resection of the primary tumor and metastatic organs with curative intent, the CHFR‐RMV high group had significantly worse recurrence‐free survival (RFS) compared with the CHFR‐RMV low group (p = 0.001). Multivariate analysis revealed that CHFR‐RMV was a significant independent prognostic factor (hazard ratio = 2.63 (1.29–5.36); p = 0.008). In the patients who had undergone resection of the primary tumor with metastatic organs with curative intent after neoadjuvant systemic chemotherapy, the SOX11‐RMV high group had significantly worse RFS compared with the SOX11‐RMV low group (p = 0.004). Conclusions The current study showed the usefulness of ctDNA methylation analysis for predicting the possibility of curative resection and long‐term outcomes after resection in Stage IV CRC. A future prospective study is needed to obtain more conclusive results.

Prognostic utility of circulating tumor DNA methylation analysis in stage IV colorectal cancer